Sonnet BioTherapeutics Updates Principal Executive Offices
| Field | Detail |
|---|---|
| Company | Sonnet Biotherapeutics Holdings, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, address-change
TL;DR
Sonnet BioTherapeutics moved its HQ to Princeton, NJ.
AI Summary
On July 18, 2025, Sonnet BioTherapeutics Holdings, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 100 Overlook Center, Suite 102, Princeton, New Jersey, 08540. This is a routine filing to update the company's address information with the SEC.
Why It Matters
This filing informs investors and stakeholders of the company's new physical location for its main operations. It's a procedural update that ensures regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative update regarding the company's address and does not involve any material financial or operational changes.
Key Players & Entities
- Sonnet BioTherapeutics Holdings, Inc. (company) — Registrant
- 100 Overlook Center, Suite 102, Princeton, New Jersey, 08540 (location) — New Principal Executive Offices
- July 18, 2025 (date) — Date of Report
FAQ
What is the new address for Sonnet BioTherapeutics Holdings, Inc.'s principal executive offices?
The new address is 100 Overlook Center, Suite 102, Princeton, New Jersey, 08540.
What is the filing date of this 8-K report?
The report was filed on July 18, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Sonnet BioTherapeutics Holdings, Inc.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (609) 375-2227.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 18, 2025 regarding Sonnet BioTherapeutics Holdings, Inc..